{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumor+of+the+Lung&page=12", "query": { "condition": "Neuroendocrine Tumor of the Lung", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 543, "total_pages": 55, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumor+of+the+Lung&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumor+of+the+Lung&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T07:20:57.629Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02589522", "title": "Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Lung Neuroendocrine Neoplasm", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Lung Small Cell Carcinoma", "Metastatic Malignant Neoplasm in the Brain", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Berzosertib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Whole-Brain Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2017-05-22", "completion_date": "2027-09-17", "has_results": true, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-15T07:20:57.629Z", "location_count": 9, "location_summary": "Duarte, California • Sacramento, California • Jacksonville, Florida + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02589522" }, { "nct_id": "NCT06146920", "title": "Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Evaluation of ctDNA using the F1T after 1 year of immunotherapy", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2024-01-10", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-15T07:20:57.629Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06146920" }, { "nct_id": "NCT00121420", "title": "Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasm Metastasis", "Brain Neoplasms" ], "interventions": [ { "name": "Motexafin gadolinium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2014-05-09", "last_synced_at": "2026-10-15T07:20:57.629Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Aurora, Colorado • Cleveland, Ohio + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00121420" }, { "nct_id": "NCT02122861", "title": "Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma - Currently Enrolling", "Non-small Cell Lung Cancer - Enrollment Completed", "Sarcoma - Enrollment Completed" ], "interventions": [ { "name": "ID-LV305", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 47, "start_date": "2014-05-30", "completion_date": "2018-12-15", "has_results": false, "last_update_posted_date": "2019-03-06", "last_synced_at": "2026-10-15T07:20:57.629Z", "location_count": 7, "location_summary": "San Francisco, California • New Haven, Connecticut • Boston, Massachusetts + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02122861" }, { "nct_id": "NCT03841110", "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Lymphoma", "Gastric Cancer", "Colorectal Cancer", "Head and Neck Cancer", "Squamous Cell Carcinoma", "EGFR Positive Solid Tumor", "HER2-positive Breast Cancer", "Hepatocellular Carcinoma", "Small Cell Lung Cancer", "Renal Cell Carcinoma", "Pancreas Cancer", "Melanoma", "NSCLC", "Urothelial Carcinoma", "Cervical Cancer", "Microsatellite Instability", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "FT500", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2019-02-15", "completion_date": "2022-11-15", "has_results": false, "last_update_posted_date": "2023-05-01", "last_synced_at": "2026-10-15T07:20:57.629Z", "location_count": 4, "location_summary": "San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03841110" }, { "nct_id": "NCT02783300", "title": "An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "GSK3326595", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 297, "start_date": "2016-08-30", "completion_date": "2023-08-30", "has_results": true, "last_update_posted_date": "2025-03-10", "last_synced_at": "2026-10-15T07:20:57.629Z", "location_count": 6, "location_summary": "Denver, Colorado • Miami, Florida • New York, New York + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02783300" }, { "nct_id": "NCT03207867", "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC, Non Small Cell Lung Cancer", "RCC, Renal Cell Cancer", "Pancreatic Cancer", "Urothelial Cancer", "Head and Neck Cancer", "DLBCL, Diffused Large B Cell Lymphoma", "MSS, Microsatellite Stable Colon Cancer", "TNBC, Triple Negative Breast Cancer", "Melanoma", "mCRPC, Metastatic Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "NIR178", "type": "DRUG" }, { "name": "PDR001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 315, "start_date": "2017-08-28", "completion_date": "2023-02-14", "has_results": true, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-10-15T07:20:57.629Z", "location_count": 5, "location_summary": "Santa Monica, California • Tampa, Florida • Baltimore, Maryland + 2 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Houston", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03207867" }, { "nct_id": "NCT04137900", "title": "Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Unresectable Solid Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "TAB004", "type": "DRUG" }, { "name": "Toripalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TopAlliance Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 499, "start_date": "2019-10-30", "completion_date": "2026-03", "has_results": false, "last_update_posted_date": "2024-02-05", "last_synced_at": "2026-10-15T07:20:57.629Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04137900" }, { "nct_id": "NCT02014116", "title": "A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Neoplasm Metastasis", "Melanoma", "Carcinoma, Non-Small-Cell Lung", "Colorectal Neoplasms" ], "interventions": [ { "name": "LY3009120 capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2013-11-26", "completion_date": "2018-10-05", "has_results": true, "last_update_posted_date": "2019-12-27", "last_synced_at": "2026-10-15T07:20:57.629Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02014116" }, { "nct_id": "NCT06870487", "title": "A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Peripheral T Cell Lymphoma", "Diffuse Large B-cell Lymphoma", "Classical Hodgkin Lymphoma", "Head and Neck Squamous Cell Carcinoma", "Melanoma", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "PF-08046032", "type": "DRUG" }, { "name": "Sasanlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2025-05-08", "completion_date": "2026-04-23", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-15T07:20:57.629Z", "location_count": 3, "location_summary": "San Antonio, Texas • Seattle, Washington", "locations": [ { "city": "San Antonio", "state": "Texas" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06870487" } ] }